Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ProMetic Life Sciences has reported positive results of its orally-active PBI-1402 compound in clinical trial in patients with chemotherapy-induced anemia.
Subscribe to our email newsletter
Results demonstrated that a once daily oral treatment of PBI-1402 induces a significant increase in hemoglobin level, red blood cell (RBC) count and hematocrit in chemotherapy-induced anemia (CIA) patients.
Furthermore, results suggest that PBI-1402 can reduce the need for RBC transfusion, since only 6% of patients in the clinical trial required transfusion.
Pierre Laurin, president and CEO of ProMetic, said: “This data further supports that PBI-1402’s current performance is in line with the FDA’s recommendation of reducing patient need for RBC transfusions.”